Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.43 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 4/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427029 | 1.00 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL29952604 | 0.85 | MGLL (0.50) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL581357 | 0.85 | MGLL (0.50) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL1396618 | 0.83 | MGLL (0.52) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL23191274 | 0.81 | ALDH1A1 (0.45) | MEN1KMT2A | |
| SCHEMBL319539 | 0.79 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL29525163 | 0.79 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL29689581 | 0.79 | CES2 (0.50) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL29955080 | 0.79 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 | |
| SCHEMBL1094432 | 0.79 | MGLL (0.48) | MGLLTRPV6ORAI1ORAI2ORAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-26 | — | — | US | disclosed |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-19 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-3523311-B1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-07 | — | — | EP | disclosed |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-01-05 | — | — | US | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-11207298-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-28 | — | — | US | disclosed |
| US-20210069155-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-11 | — | — | US | disclosed |
| EP-3151833-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2017-04-12 | — | — | EP | disclosed |
| US-9604937-B2 | Pyrimidine-2,4-diamine derivatives for treatment of cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2017-03-28 | — | — | US | disclosed |
| US-20160002175-A1 | Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2016-01-07 | — | — | US | disclosed |
| WO-2015187089-A1 | MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| EP-2925744-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | Thomas Helledays Stiftelse För Medicinsk Forskning (SE) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014084778-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES FOR TREATMENT OF CANCER | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2014-06-05 | — | — | WO | disclosed |
| US-20110136877-A1 | 2-PHENYL PHENOXYACETIC ACIDS USEFUL FOR TREATING INFLAMMATORY DISORDERS | LIGAND PHARMACEUTICALS INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136877-A1 | 2-PHENYL PHENOXYACETIC ACIDS USEFUL FOR TREATING INFLAMMATORY DISORDERS | HCAR2, PAH, PTGES2 | MGLL 2490/4885TRPV6 682/4885ORAI1 3279/4885 |
| US-20160002175-A1 | Pyrimidine-2,4-Diamine Derivatives for Treatment of Cancer | DPYD, MTHFD1, TYMS | MGLL 4273/4885TRPV6 4136/4885ORAI1 4364/4885 |
| US-11207298-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | MGLL 4717/4885TRPV6 1068/4885ORAI1 2507/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | MGLL 599/4885TRPV6 2192/4885ORAI1 1719/4885 |
| US-20230000833-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | MGLL 4717/4885TRPV6 1068/4885ORAI1 2507/4885 |
| US-11759455-B2 | Substituted 1H-imidazo[4,5-b]pyridin-2(3H)-ones and their use as GLUN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | MGLL 4717/4885TRPV6 1068/4885ORAI1 2507/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | MGLL 1804/4885TRPV6 4597/4885ORAI1 4707/4885 |
| US-20210069155-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | MGLL 4717/4885TRPV6 1068/4885ORAI1 2507/4885 |
| US-20230338341-A1 | SUBSTITUTED 1H-IMIDAZO[4,5-b]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | MGLL 4717/4885TRPV6 1068/4885ORAI1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.